REVIEW

X-linked retinoschisis: an update

Stephen K Sikkink, Susmito Biswas, Neil R A Parry, Paulo E Stanga, Dorothy Trump

J Med Genet 2007;44:225–232. doi: 10.1136/jmg.2006.047340

X-linked retinoschisis is the leading cause of macular degeneration in males and leads to splitting within the inner retinal layers leading to visual deterioration. Many missense and protein truncating mutations have now been identified in the causative retinoschisis gene (RS1) which encodes a 224 amino acid secreting retinal protein, retinoschisin. Retinoschisin octamerises is implicated in cell–cell interactions and cell adhesion perhaps by interacting with β 2 laminin. Mutations cause loss of retinoschisin function by one of the three mechanisms: by interfering with protein secretion, by preventing its octamerisation or by reducing function in the secreted octamerised protein. The development of retinoschisis mouse models have provided a model system that closely resembles the human disease. Recent reports of RS1 gene transfer to these models and the sustained restoration of some retinal function and morphology suggest gene replacement may be a possible future therapy for patients.

PREVALENCE AND EPIDEMIOLOGY

XLRS is the leading cause of juvenile macular degeneration in males¹⁷ with an estimated prevalence of between 1 in 15 000 and 1 in 30 000.¹⁸ These figures, based on the Finnish population, are similar to the data from a clinical study of XLRS in The Netherlands.¹⁹ Many of the mutations described in the gene have been identified in more than one family⁹ with some indication of founder effect. This is particularly marked in Finland, with three mutations accounting for almost all cases,²⁰ illustrating the allelic homogeneity in Finland.²¹ The wider worldwide genetic heterogeneity suggests that the worldwide prevalence may be lower than these estimates. However, it is likely that XLRS is still underdiagnosed.

CLINICAL FEATURES

There is a great variation in disease severity even among individuals who have the same causative RS1 mutation,^{22–25} and no correlation has been identified between mutation type and disease severity or progression.²³ Patients often present at school age with poor vision and reading difficulties, although this can vary with patients presenting as young as 3 months.²⁶ The age of onset follows a bimodal distribution with patients presenting in infancy with squint and nystagmus and those with only poor vision presenting at school age.²⁶ Visual impairment is variable with best-corrected visual acuity from 20/20 to 20/600^{17 27} and marked differences are found at all ages even within a family or in patients with the same mutation.²³ Foveal schisis (retinal splitting), seen as a cartwheel pattern of folds radiating out from the fovea (fig 1), is the characteristic sign of XLRS and is present in 98–100% of cases.^{27–29} However, over time this may become less distinct.²⁷ Peripheral retinoschisis is often noted in the inferotemporal region. During infancy, these cavities may be very large bullous retinoschisis,²⁶ and this generally regresses leaving lines of pigment in older patients.^{26 27} More than half the patients have some peripheral retinoschisis,²⁷ which can vary from shallow schisis to marked elevation in the inner leaflet over a large retinal area. Breaks occur within the inner layer varying from small holes to large tears,²⁷ and fragmentation of the inner leaf can lead to membranous remnants referred to as vitreous veils. Vessels crossing between the walls of the schisis may be unsupported and at risk of haemorrhage. Additional peripheral changes may include pigmentation, which can resemble retinitis

X-linked retinoschisis (XLRS) is a retinal dystrophy caused by mutations in the RS1 gene in Xp22.1, which leads to schisis (splitting) of the neural retina leading to reduced visual acuity in affected men (OMIM #312700). The condition accounts for almost all congenital retinoschisis with occasional reports of autosomal dominant retinoschisis making up the remainder.¹ The split in the retina occurs predominantly within the inner retinal layers and is very different from retinal detachment, which is a split between the neural retina and the retinal pigment epithelium.

XLRS was first described in the 19th century² and documented as X linked in 1913.³ Several cases were then described but were given alternative names including neuroretinal disease in men⁴ and congenital vascular veils in the retina.⁵ The term “X linked retinoschisis” was first used in 1953⁶ and this, together with “juvenile retinoschisis,”⁷ is now the generally accepted term.

The causative gene RS1 was identified in 1997⁸ and numerous inactivating mutations have since been found⁹ (<http://www.dmd.nl/rs/index.html>). Investigation of the protein retinoschisin, encoded by RS1, has revealed it to be a secretory protein, containing a discoidin domain and functioning as an octamer.^{10–13} Three retinoschisis mouse models have been developed and they have similar retinal pathology to the human disease.^{14–16} This article aims to review the clinical, pathological and electrophysiological features of XLRS, our current understanding of its molecular basis and to consider future therapy.

See end of article for authors' affiliations

Correspondence to: Professor D Trump, Academic Unit of Medical Genetics, University of Manchester, St Mary's Hospital, Manchester M13 0JH, UK; dorothy.trump@manchester.ac.uk

Received 30 October 2006
Revised 5 December 2006
Accepted 8 December 2006

Abbreviations: CSNB, congenital stationary night blindness; ERG, electroretinogram; OCT, optical coherence tomography; RS1, retinoschisis gene; XLRS, X-linked retinoschisis

Figure 1 Red-free (top) and colour photographs (bottom) of macular region in X-linked retinoschisis. The radial cystic lesions at the macula are more obvious on the red-free image.

pigmentosa, sublinear retinal fibrosis, white retinal flecks and vascular attenuation or sheathing.²⁷ In a proportion of patients an inner retinal reflex resembling a tapetal reflex is observed.²⁷

Visual function is often stable from childhood until the 40s when deterioration occurs,^{17 23 27} but complications, including vitreous haemorrhage (up to a third of patients)^{27 28} and retinal detachment (up to 20% patients^{27 29}), may lead to severe visual impairment. Most retinal detachments associated with XLRs are rhegmatogenous in origin owing to the development of peripheral retinal breaks. Bilateral macular detachments possibly caused by abnormal vitreomacular traction have also been reported.³⁰ Sudden visual loss secondary to vitreous haemorrhage is an occasional presenting feature in older children. Leucocoria associated with tractional retinal detachment caused by an organised vitreous haemorrhage has been reported in a 9 month old infant.³¹ In such cases it is of importance to exclude other causes of leucocoria, such as retinoblastoma, Coats' disease, Norrie's disease, retinal detachment and retinopathy of prematurity and vitreoretinopathies. Axial hypermetropia also appears to be a consistent feature of XLRs.³²

In general females who are heterozygous for an RS1 mutation remain asymptomatic and have no clinical features of the condition,^{28 33} although we have recently seen a young girl with the clinical features of XLRs1 and a reduced b-wave on electroretinogram (ERG).³⁴ The patient has an affected father and is heterozygous for his mutation with no other RS1 mutation. It is likely that she has skewed X inactivation accounting for her clinical features. The only other case of affected females in the literature is from one highly consanguineous family from Columbia in which three females are affected and all are homozygous for a frameshift mutation (639delG).³⁵

INVESTIGATIONS

The clinical diagnosis of XLRs can be challenging and a delay in diagnosis averaging 8 years after the onset of symptoms has been documented.²⁷ Subtle foveal schisis can be difficult to

observe ophthalmoscopically, but may be more apparent on red-free illumination (fig 1). To this end, digital fundus photography with colour and red-free illumination can be very helpful. Electrodiagnostic testing is useful in both supporting or suggesting the diagnosis.

The ERG, (fig 2) is the electrical response of the retina to a flash of light that can be recorded at the cornea. It is recorded with the retina in a dark-adapted (scotopic) or light-adapted (photopic) state. The International Society for Clinical Electrophysiology of Vision publishes standard protocols for adult ERG examination, although often there has to be some compromise when testing children.³⁶ The ERG comprises several component potentials that originate from different stages of retinal processing, which overlap in time. Although there are many components of the ERG, it is the relative contributions of the a-wave and b-wave that are of particular interest in XLRs. The a-wave arises by suppression of a circulating dipole current generated by photoreceptors by a light stimulus and produces a negative going a-wave. Although the early (12–15 ms) portion of the a-wave is thus directly related to photoreceptor function, there is a postreceptoral element as the wave progresses.³⁷ The larger corneo-positive b-wave, which truncates the negative a-wave, is largely generated by the activity of depolarising bipolar cells within the inner retina.³⁸ Patients with XLRs show a characteristic pattern on the ERG (fig 2), which is best detected after dark adaptation and using a standard, Ganzfeld, bright white flash stimulus. A reduction in the amplitude of the b-wave and a relative preservation of the negative a-wave gives rise to the so-called electronegative ERG. Reduced b-wave amplitudes indicate an inner retinal abnormality.^{28 29 39 40} Further evidence for the selective effect on ON-bipolars may be seen by separating on and off responses using long-duration (200 ms) stimuli.⁴¹

The characteristic negative ERG is not unique to XLRs and is seen in a variety of other hereditary and acquired retinal disorders, most notably congenital stationary night blindness (CSNB). Electrophysiology can show some differences between XLRs and the complete and incomplete forms of CSNB,⁴¹ but an

Figure 2 Electrophoretogram (ERG) recordings from the left eye of two other patients with X-linked retinoschisis (A) aged 8 years and (B) aged 6 years, and one normal control individual (C) aged 6 years. All used International Society for Clinical Electrophysiology of Vision-standard stimulation but followed a paediatric protocol,³⁶ using a gold-mylar skin electrode (Burden Neuroscience, Bristol, UK) mounted on the lower eyelid, with outer canthus reference. (A) and (B) exhibit reduced and delayed scotopic flash and flicker ERGs (top and middle rows), but the key feature is the reduced dark-adapted b-wave (bottom row) with b:a ratios of 1.27 and 1.43, in comparison with the C's b:a ratio of 2.37. For adult ERG findings see Holder *et al* and Stanga *et al*.^{41, 48}

important factor in making the differential diagnosis is their quite different presentations (see Differential diagnosis). Nevertheless, the variation of b:a ratio is considered to be an important diagnostic parameter.⁴² In the early stage of disease, the a-wave is often normal but the amplitude may reduce with disease progression and we have found that up to a third of patients do have a reduction in their a-wave,⁴³ indicating the photoreceptor involvement in the disease. However, it is clear from a number of studies that not all individuals with XLRs show the classic electronegative ERG, and b-wave amplitudes may not be significantly different from normal.^{43–46} The ERG phenotype shows a wide variability between, as well as within, families with different genotypes, indicating considerable heterogeneity of ERG response without clinical, age or genetic correlations,²² thus it cannot be relied on as the sole investigation for XLRs.

A recent addition to the armamentarium of useful investigations for XLRs is optical coherence tomography (OCT) (fig 3). This is a non-invasive, non-contact procedure that uses low coherence interferometry to detect relative reflection changes and different optical surfaces. The wavelength is close to infrared and is thus well tolerated. With resolutions approaching 10 µm it can be used to diagnose and monitor retinal disease. Its value in retinoschisis has been well demonstrated in many reports.^{47–51} Typically, it can produce a two-dimensional cross-sectional image of structures in the eye. The OCT can scan across the macular and perimacular region in a variety of orientations. The images produced clearly show the splitting of retina, which in many cases involves more than one layer. Cleavage can be seen in or just below the superficial nerve fibre layer and also, to a variable extent, in deeper layers. The other characteristic features that are seen are thin walled, vertical palisades spanning the cleft between the split retinal layers and giving rise to the cystic-like spaces in the perifoveal region (fig 3). These cystic-like spaces have a tendency to enlarge and become confluent as they approach the fovea. An advantage of the OCT is that it can show splitting of retinal layers even when this is not clinically observed. Later stages of the disease are associated with atrophic changes in the macula. These can be observed with OCT as a generalised reduction of the foveal thickness.

A recent adaptation combining scanning laser ophthalmoscopy and OCT-termed three-dimensional OCT, can produce transverse and longitudinal images of the retina and demonstrates that splitting can occur in any layer in the retina.⁵² Although the investigation is useful, there does not appear to be any correlation between the OCT characteristics of the central macular region and the visual acuity.⁵³

The cystic-like spaces do not demonstrate hyperfluorescence when undertaking fluorescein angiography, in contrast with that observed in cystoid macular oedema. Indocyanin green angiography on the other hand is capable of demonstrating the cystic-like spaces centred on the foveola,⁵⁴ although this modality is more invasive than OCT.

Genetic testing can now be performed to confirm a diagnosis. Mutations can be detected in 90–95% of patients who have a clinical diagnosis when all six exons and splice junctions are sequenced (see below). Identifying the causative mutation in an affected man is very helpful, both for confirmation of the diagnosis and in genetic counselling as females who are at risk of carrying the mutation can be offered genetic testing.

MANAGEMENT

It is often helpful for patients to have an explanation of the usual disease progression, which may stabilise in the teens until middle age, and of the remarkable differences in disease severity among family members,^{22–25} which indicates that disease onset and rate of progression cannot be predicted by either mutation analysis or by comparisons with other affected relatives. Many affected children benefit from correction of refractive correction, low vision aids and educational support. Currently, there is no treatment of the retinal degeneration and treatment of the schisis cavities is usually not indicated. One recent report describes successful treatment of schisis cavities with topical dorzolamide (carbonic anhydrase inhibitor).⁵⁵ Seven out of eight patients treated had an improvement in the degree of cystic foveal lesions in at least one eye when measured using OCT and six of these patients had a modest improvement in visual acuity. These are interesting results but additional studies are required to assess how long the effects are maintained and whether there is a sustained improvement in functional vision.

Figure 3 Optical coherence tomography images of the macular region from the same patient as fig 1. Top and bottom left showing schisis through multiple inner layers of the retina in right and left eyes, respectively. Macular thickness maps showing central macular thickening diffuse in right and more focal in the left eye.

Vitreous haemorrhage when not associated with retinal detachment usually resolves spontaneously. In the event of severe complications such as retinal detachment and vitreous haemorrhage, surgical intervention may be required. Regillo *et al*⁵⁶ evaluated surgical management of six eyes from four patients with XLRS1 using scleral buckling for retinal detachment and vitrectomy for vitreous haemorrhage or proliferative vitreoretinopathy. Anatomical success and ambulatory vision was achieved in five of the six eyes with a mean follow-up of 3.8 years. However, two of the four eyes treated by primary scleral buckling eventually required vitrectomy. Recent reports of using perfluorocarbon liquid or perfluorodecalin during vitrectomy to repair retinoschisis-associated retinal detachments has shown promising results.^{57 58}

Families often benefit from genetic counselling to explain the X-linked inheritance pattern and recurrence risks in future offsprings. If a genetic diagnosis has been made with the identification of the causative mutation, then women who are at risk of carrying the mutation can be offered genetic testing. It is particularly important to explain the extreme variation in severity even within families since, for example, affected brothers might have very different disease.²³

DIFFERENTIAL DIAGNOSIS

The identification of foveal schisis in a male, associated with a reduced b-wave on ERG and a family history consistent with

X-linked inheritance, makes the diagnosis very likely. This can be confirmed by molecular genetic studies. X-linked inheritance and electronegative dark-adapted ERG, as previously stated, is not confined to XLRS. The chief differentials are X linked CSNB type 1 (MIM #310500) and type 2 (MIM #300071). Ophthalmoscopically visible fundus changes may not be visible in either XLRS or XLCSNB and both may present with nystagmus, although it is more common in CSNB. A clear history of nyctalopia would direct one to the correct diagnosis. Furthermore, myopia is typical of XLCSNB in contrast with the hypermetropia which is frequent in XLRS.

Flat b-waves on ERG testing are also associated with a variety of postphototransduction disorders of the inner retina representing between 2.9% and 4.8% of all ERGs recorded in tertiary referral centres.^{59 60} The ERG findings should be taken in the context of other clinical features to support the diagnosis.

Cystic changes in the macula may be due to a variety of causes. Most frequent of these is macular oedema, which is often owing to conditions such as retinal vein occlusion, diabetic retinopathy, uveitis, retinitis pigmentosa and even dominantly inherited cystoid macular oedema,⁶¹ although the associated clinical features and leakage on fluorescein angiography accompanying these disorders rarely lead to diagnostic confusion. There are also descriptions of possible autosomal recessive foveal schisis.^{62 63} The second of these descriptions describes female patients with foveal schisis but no additional

retinal abnormalities and normal electrodiagnostic testing. The foveal findings looked somewhat different from those in XLRS.⁶³ A more recently recognised syndrome of macular retinoschisis in highly myopic eyes with posterior staphyloma has been characterised by OCT, demonstrating splitting of the inner and outer retinal layers within the macular region.⁶⁴ OCT performed for optic nerve pit maculopathy demonstrates foveal retinoschisis that may be secondary to posterior vitreous traction.⁶⁵ In this condition a small pit is visible at the temporal edge of the optic disc.

Degenerative retinoschisis tends to involve the peripheral retina with splitting of the outer retinal layers. The condition tends to be unilateral, occurring in an older age group and is not associated with ERG abnormalities or RS1 mutations.⁶⁶

Other conditions which should be differentiated from XLRS1 include the rare autosomal recessive condition, Goldmann-Favre syndrome, caused by mutations in the gene NR2E3,⁶⁷ which can lead to foveal schisis, but the associated nyctalopia and pigmentary clumping should help to differentiate this from XLRS. In addition, the ERG is usually extinguished. Niacin, occasionally prescribed for familial hyperlipidaemia, has been shown to cause a reversible cystic maculopathy.⁶⁸ As in XLRS, these cysts fail to show leakage on fluorescein angiography, but are demonstrated on OCT affecting both the outer plexiform and inner nuclear layers.⁶⁹ An unusual autosomal dominant retinoschisis with both macular and peripheral involvement has been reported in which male-to-male transmission was documented. The ERG responses in six out of eight failed to demonstrate any abnormality.¹

PATHOLOGY

Few affected eyes have been available for study, although investigation of retinoschisis mouse models has greatly assisted these investigations¹⁴⁻¹⁶. Condon *et al*⁷¹ examined one surgically enucleated and two postmortem eyes from two related men with XLRS and this was followed up with investigation of the globes from three further patients (two of whom were related).⁷² These studies delineated the pathology in the inner retina describing the characteristic abnormality: a split (or schisis) within the superficial retinal layers, the inner limiting membrane, the nerve fibre layer and the ganglion cell layer, the inner leaflet of the schisis consisting of inner limiting membrane, fragments of Müller cells (glial cells) and blood vessels. The ganglion cell layer is thinned with marked degeneration of the overlying photoreceptors associated with thinning of the inner nuclear layer.⁷² The schisis cavity, the inner and outer schisis layers, and the surrounding retina are described as containing an amorphous eosinophilic PAS-positive material that is filamentous and thought to originate from Müller cells.⁷²

MOLECULAR GENETICS

The RS1 gene (OMIM# 312700), which maps to Xp22, was identified late in 1997 after an extensive positional cloning effort by a number of groups⁸ and has six exons with a cDNA of 3.1 kb. RS1 is expressed exclusively in the retina⁸ by photoreceptors and bipolar cells^{10 73} and encodes retinoschisin, a 224 amino acid secretory protein of 24 kDa, which is detected throughout all layers in the neural retina despite the restricted pattern of gene expression.^{10 73 74}

Retinoschisin has a signal peptide allowing transport into the endoplasmic reticulum for trafficking through the secretory pathway and a single discoidin domain which contains 10 cysteine residues.^{8 10} Discoidin domains (also known as the F5/8 type C domains) are found in a family of extracellular cell surface proteins and are involved in cell adhesion and signalling.⁷⁵ The discoidin domain receptors, for example,

which are transmembrane tyrosine kinase receptors, interact through their discoidin domains with collagens and regulate cell adhesion and extracellular matrix remodelling.⁷⁵ Other proteins containing a discoidin domain include blood coagulation factors 5 and 8, milk fat globule protein, neuropilins 1 and 2 and neuroligin IV.⁷⁶ The cysteine residues within the retinoschisin discoidin domain are critical for folding and the formation of functional retinoschisin dimers and ultimately octamers.¹¹ Disulphide bonds between two pairs of cysteine residues (Cys63-Cys219 and Cys110-Cys142) stabilise the folded monomeric retinoschisin subunits and additional disulphide bonded pairs of cysteines link the subunits into dimers (Cys40-Cys40) and octamers (Cys59-Cys223).¹¹ Disruption of these bonds interferes with dimer and octamer formation.¹¹

Retinoschisin is believed to function in cell adhesion in the development and maintenance of retinal architecture. This is in keeping with other proteins containing discoidin domains and is supported by the observations in patients and in the mouse models. A wave of expression begins during retinal development immediately after neuronal birth and terminal differentiation as neuronal cell type is born⁷⁷ and is then maintained in adult life.

The molecular interactions of retinoschisin and its molecular role in maintenance of retinal integrity have yet to be fully elucidated. Recent data suggest retinoschisin might interact with $\beta 2$ laminin within the extracellular space and with αB crystallin intracellularly.⁷⁸ Laminins are large heterotrimeric extracellular glycoproteins thought to play a role in the development and stability of synapses.^{79 80} Deletion of the $\beta 2$ chain leads to a reduction in the amplitude of the b-wave in mice reminiscent of XLRS⁸¹ supporting a possible molecular interaction between retinoschisin and $\beta 2$ laminin. αB crystallin is an intracellular molecule which functions as a chaperone⁸² and may interact with retinoschisin as it moves through the secretory pathway. The physiological role of these potential molecular interactions and the implications for XLRS require further investigation.

MOLECULAR PATHOLOGY

Numerous RS1 mutations associated with XLRS have now been described^{9 22 25} (<http://www.dmd.nl/rs/index.html>). The mutations are predominantly missense and are clustered in exons 4–6, which encode the discoidin domain, although deletions, insertions and splice site mutations have been described. Studies of mutant retinoschisin indicate missense mutations lead to disease pathology by at least one of the following three mechanisms:^{12 13} interfering with retinoschisin secretion, allowing secretion but interfering with retinoschisin octamerisation or allowing secretion and octamerisation but interfere with protein function. The position of these mutations within the protein has helped predictions of these mechanisms.^{13 83} There is no correlation between the molecular mechanism of disease and its severity,²³ which suggests there may be other factors influencing disease severity such as genetic modifiers or environmental influences.⁸⁴

ANIMAL MODELS

To date, three mouse models exist for XLRS. In 2002, Weber *et al*¹⁴ replaced exon 3 of the murine homologue of human XLRS1 (retinoschisin-1 homologue, *XLRS1h*) in-frame with a *LacZ/Neo^r* cassette to create null mouse model (*XLRS1h*^{−/Y}) with no protein expression. Similarly in 2004, Zeng *et al*¹⁵ replaced exon 1 and 1.6 kb of intron 1 of *XLRS1h* with a *Neo^r* cassette to produce a second null-allele mouse model. More recently, the Tennessee Mouse Genome Consortium produced a mouse pedigree (44TNJ) with a retinal phenotype using an ENU-based mutagenesis screen.¹⁶ Subsequent mutation analysis of

this pedigree revealed a T→C substitution within intron 2 of *XLRS1h* which created an alternative splice site leading to three transcripts in the affected male mouse: wild type, 10bp insertion after exon 1, 26bp deletion (exon 2). Virtual protein translation showed that both alternative transcripts would form premature stop codons in *XLRS1h*, although further investigation is required to determine if these truncated *XLRS1h* peptides are expressed in the 44TNJ mouse.¹⁶

All three *XLRS1h* knockout models displayed morphological and functional retinal phenotypes similar to human XLRS. Fundus examination revealed the presence of small cyst-like structures in the inner retina of the *XLRS1h*^{-/-} mouse¹⁴ and intraretinal flecks in 44TNJ mouse.¹⁶ Similarly, ERG analysis of all three mouse models showed a characteristic reduced dark-adapted b-wave. Histologically, the mice displayed disorganisation of retinal layers due to mislocalisation of cells within the inner plexiform, inner nuclear and outer plexiform layers; focal areas of retinal splitting or “schisis” were also evident within the inner nuclear layer and structural abnormalities of synapses occur within the outer plexiform layer.^{14–16}

GENE REPLACEMENT

The developmental and subsequent continued expression of RS1⁷⁷ and the pathology described in the mouse retina indicate that retinoschisin has an important role in both retinal development and maintenance. This suggests that XLRS is, at least initially, a developmental abnormality of retina and that gene replacement might therefore be a therapeutic possibility. This has been used with some success on both knock-out mouse XLRS models.^{15–85} In each case, the RS1 gene was delivered to the affected male mice using an adeno-associated viral vector and intraocular injection. Subsequent investigation of the retina in these animals indicated successful expression of retinoschisin in all retinal layers.^{15–85} The ERG recording was taken as a measure of retinal function and in each of these models replacement of the RS1 gene led to restoration of the b-wave amplitude.^{15–85} Min *et al*⁸⁵ also describe an improvement in the rod-mediated a-wave. These effects were maintained until at least 5 months after the injection. This group also reported an improvement in the morphology of the inner retina and photoreceptors after injection.⁸⁵ But there was no similar improvement documented in the study by Zenn *et al*,¹⁵ perhaps reflecting a difference in the viral vector and promoter used which may have resulted in increased levels of protein in the Min *et al*'s study. These results indicate sustained restoration of some retinal function and morphology and suggest that gene replacement might be a possible future treatment for patients.

However, these results should be treated with some caution. The modelling of retinoschisin in the mouse is limited as mice do not have a fovea and many patients have the disease restricted to the fovea or with only mild peripheral changes. The benefits of gene therapy for these patients may be limited and, in addition, the developmental anomalies of the retina are unlikely to be corrected by gene therapy in childhood or adult life. Furthermore the mouse models are both null mutants expressing no retinoschisin which is a different scenario to that in most patients who have missense mutations,^{9–22–25} many of which lead to intracellular retention of mutant retinoschisin. Therefore, there is a risk that gene therapy might not be effective in these patients as the presence of mutant retinoschisin might have a dominant negative effect on the wild-type molecule, interfering with its function either by causing sequestration of the wild-type protein within the cell or by the formation of octamers of wild-type and mutant protein. Expressing two alleles in one cell will be a novel situation because although women carriers have both mutant and

wild-type alleles, X-inactivation will silence one of these alleles in each cell. This needs further investigation.

SUMMARY

In summary, XLRS is an important cause of male visual loss in childhood and should be considered as a possible diagnosis in boys with reduced visual acuity and men with macular changes. Recent advances in methods of investigation, including OCT and genetic testing, complement the results of clinical examination and ERG, which is beneficial particularly given its clinical variability. To date there has been no treatment for the retinal degeneration of XLRS although the complications can be treated as they occur. The recent descriptions of gene replacement restoring some retinal function in two knockout XLRS mouse models gives hope that gene therapy may be an option for treatment in the future.

ACKNOWLEDGEMENTS

The authors are grateful to the MRC for funding the research work that led in part to this review (MRC G0000089/51849).

Authors' affiliations

Stephen K Sikkink, Dorothy Trump, Academic Unit of Medical Genetics, St Mary's Hospital, University of Manchester, Manchester, UK

Stephen K Sikkink, Dorothy Trump, Centre for Molecular Medicine, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK

Susmito Biswas, Neil R A Parry, Paulo E Stanga, Manchester Royal Eye Hospital, Oxford Road, Manchester, UK

Competing interests: None.

REFERENCES

- 1 Yassur Y, Nissenkorn I, Ben-Sira I, Kaffe S, Goodman RM. Autosomal dominant inheritance of retinoschisis. *Am J Ophthalmol* 1982;**94**:338–43.
- 2 Haas J. Ueber das Zusammenkommen von Veränderungen der Retina und Chorioidea. *Arch Augenheilkd* 1898;**37**:343–8.
- 3 Pagenstecher H. Uebereine unterdemBilde der Natzhauteiblosung verlaufende,erblicheErkrankung der Retina. *Graefes Arch Clin Exp Ophthalmol* 1913;**86**:457–62.
- 4 Thomson E. Memorandum regarding a family in which neuroretinal disease of an unusual kind occurred in only males. *Brit J Ophthalmol* 1932;**16**:681–6.
- 5 Mann I, Macrae A. Congenital vascular veils in the vitreous. *Brit J Ophthalmol* 1938;**22**:1–10.
- 6 Jager GM. A hereditary retinal disease. *Trans Ophthalmol Soc UK* 1953;**73**:617–619.
- 7 Sabates FN. Juvenile retinoschisis. *Am J Ophthalmol* 1966;**62**:683–9.
- 8 Sauer CG, Gehrig A, Warneke-Wittstock R, Marquardt A, Ewing CC, Gibson A, Lorenz B, Jurkies B, Weber BH. Positional cloning of the gene associated with X-linked juvenile retinoschisis. *Nat Genet* 1997;**17**:164–70.
- 9 The Retinoschisis Consortium. Functional implications of the spectrum of mutations found in 234 cases with X-linked juvenile retinoschisis. *Hum Mol Genet* 1998;**7**:1185–92.
- 10 Grayson C, Reid SN, Ellis JA, Rutherford A, Sowden JC, Yates JR, Farber DB, Trump D. Retinoschisin, the X-linked retinoschisis protein, is a secreted photoreceptor protein, and is expressed and released by Weri-Rb1 cells. *Hum Mol Genet* 2000;**9**:1873–9.
- 11 Wu WW, Molday RS. Defective discoidin domain structure, subunit assembly, and endoplasmic reticulum processing of retinoschisin are primary mechanisms responsible for X-linked retinoschisis. *J Biol Chem* 2003;**278**:28139–46.
- 12 Wu WW, Wong JP, Kast J, Molday RS. RS1, a discoidin domain-containing retinal cell adhesion protein associated with X-linked retinoschisis, exists as a novel disulfide-linked octamer. *J Biol Chem* 2005;**280**:10721–30.
- 13 Wang T, Zhou A, Waters CT, O'Connor E, Read RJ, Trump D. Molecular pathology of X-linked retinoschisis: mutations interfere with retinoschisin secretion and oligomerisation. *Br J Ophthalmol* 2006;**90**:81–6.
- 14 Weber BH, Schrewe H, Molday LL, Gehrig A, White KL, Seeliger MW, Jaissle GB, Friedburg C, Tamm E, Molday RS. Inactivation of the murine X-linked juvenile retinoschisis gene, *Rs1h*, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure. *Proc Natl Acad Sci USA* 2002;**99**:6222–7.
- 15 Zeng Y, Takada Y, Kjellstrom S, Hiriyanna K, Tanikawa A, Wawrousek E, Smaoui N, Caruso R, Bush RA, Sieving PA. RS-1 Gene delivery to an adult *Rs1h* knockout mouse model restores ERG b-wave with reversal of the electronegative waveform of X-linked retinoschisis. *Invest Ophthalmol Vis Sci* 2004;**45**(9):3279–85.

- 16 Jablonski MM, Dalke C, Wang X, Lu L, Manly KF, Pretsch W, Favor J, Pardue MT, Rinchik EM, Williams RW, Goldowitz D, Graw J. An ENU-induced mutation in *Rs1h* causes disruption of retinal structure and function. *Mol Vis* 2005;11:569–81.
- 17 Forsius H, Krause U, Helve J, Voupala V, Mustonen E, Vainio-Mattila B, Fellman J. Visual acuity in 183 cases of X-chromosomal retinoschisis. *Can J Ophthalmol* 1973;8:385–393.
- 18 De La Chappelle A, Alitalo T, Forsius H. X-linked juvenile retinoschisis. In: Wright AF, Jay B, eds. *Molecular Genet Inherited Eye Disorders*. Switzerland: Harwood Academic Publishers, 1994;339–57.
- 19 van Schooneveld MJ. X-linked juvenile retinoschisis. Amsterdam: Netherlands Ophthalmic Research Institut, 1997:113.
- 20 Huopaniemi L, Rantala A, Forsius H, Somer M, de la Chapelle A, Alitalo T. Three widespread founder mutations contribute to high incidence of X-linked juvenile retinoschisis in Finland. *Eur J Hum Genet* 1999;7:368–76.
- 21 Peltonen L, Jalanko A, Varilo T. Molecular genetics of the Finnish disease heritage. *Hum Mol Genet* 1999;8:1913–23.
- 22 Eksandh LC, Ponjavic V, Ayyagari R, Bingham EL, Hiriyanna KT, Andreasson S, Ehinger B, Sieving PA. Phenotypic expression of juvenile X-linked retinoschisis in Swedish families with different mutations in the *XLRS1* gene. *Arch Ophthalmol* 2000;118:1098–104.
- 23 Pimenides D, George ND, Yates JR, Bradshaw K, Roberts SA, Moore AT, Trump D. X-linked retinoschisis: clinical phenotype and *RS1* genotype in 86 UK patients. *J Med Genet* 2005;42:e35.
- 24 Shinoda K, Ishida S, Oguchi Y, Mashima Y. Clinical characteristics of 14 Japanese patients with X-linked juvenile retinoschisis associated with *XLRS1* mutation. *Ophthalmic Genet* 2000;21:171–80.
- 25 Simonelli F, Cennamo G, Ziviello C, Testa F, de Crecchio G, Nesti A, Manitto MP, Ciccodicola A, Banfi S, Brancato R, Rinaldi E. Clinical features of X-linked juvenile retinoschisis associated with new mutations in the *XLRS1* gene in Italian families. *Br J Ophthalmol* 2003;87:1130–4.
- 26 George ND, Yates JR, Bradshaw K, Moore AT. Infantile presentation of X-linked retinoschisis. *Br J Ophthalmol* 1995;79:653–7.
- 27 George ND, Yates JR, Moore AT. Clinical features in affected males with X-linked retinoschisis. *Arch Ophthalmol* 1996;114:274–80.
- 28 Deutmann AF. *The hereditary dystrophies of the posterior pole of the eye*. Assen: Van Gorcum, 1971.
- 29 Kellner U, Brummer S, Foerster MH, Wessing A. X-linked congenital retinoschisis. *Graefes Archive Ophthalmol* 1990;228:432–7.
- 30 Garg SJ, Lee HC, Grand MG. Bilateral macular detachments in X-linked retinoschisis. *Arch Ophthalmol* 2006;124:1053–5.
- 31 Prasad A, Wagner R, Bhagat N. Vitreous hemorrhage as the initial manifestation of X-linked retinoschisis in a 9-month-old infant. *J Pediatr Ophthalmol Strabismus* 2006;43:56–8.
- 32 Kato K, Miyake Y, Kachi S, Suzuki T, Terasaki H, Kawase Y, Kanda T. Axial length and refractive error in X-linked retinoschisis. *Am J Ophthalmol* 2001;131:812–4.
- 33 Vainio-Mattila B, Eriksson AW, Forsius H. X-chromosomal recessive retinoschisis in the region of Pori. *Acta Ophthalmologica* 1969;47:1135–48.
- 34 Saldana M, Sheridan E, Thompson J, Monk E, Doran RD, Trump D, Long V. X-linked retinoschisis in the female with a heterozygous *RS1* missense mutation. *Am J Med Genetics*, 2006;in press.
- 35 Mendoza-Londono R, Hiriyanna KT, Bingham EL, Rodriguez F, Shastri BS, Rodriguez A, Sieving PA, Tamayo ML. A Colombian family with X-linked juvenile retinoschisis with three affected females finding of a frameshift mutation. *Ophthalmic Genet* 1999;20:37–43.
- 36 Marmor MF, Zrenner E. Standard for clinical electroretinography (1999 update). *Doc Ophthalmol* 1998;97:143–56.
- 37 Bush RA, Sieving PA. A proximal retinal component in the primate photopic ERG a-wave. *Invest Ophthalmol Vis Sci* 1994;35:635–45.
- 38 Forrester J, Dick A, McMenamin P, Lee W. *The eye basic sciences in practice*. London: Saunders, 1996.
- 39 Tanino T, Katsumi O, Hirose T. Electrophysiological similarities between two eyes with X-linked retinoschisis. *Doc Ophthalmol* 1985;60:149–61.
- 40 Peachey NS, Fishman GA, Derlacki DJ, Brigell MG. Psychophysical and electroretinographic findings in X-linked juvenile retinoschisis. *Arch Ophthalmol* 1987;105:513–6.
- 41 Holder GE, Robson AG. Genetically determined disorders of retinal function. In: Clescia GG, eds. *Disorders of visual processing*. Vol 5: Elsevier, 2005;271–194.
- 42 Tanimoto N, Usui T, Takagi M, Hasegawa S, Abe H, Sekiya K, Miyagawa Y, Nakazawa M. Electroretinographic findings in three family members with X-linked juvenile retinoschisis associated with a Novel Pro192Thr mutation of the *XLRS1* gene. *Jpn J Ophthalmol* 2002;46:568–76.
- 43 Bradshaw K, George N, Moore A, Trump D. Mutations of the *XLRS1* gene cause abnormalities of photoreceptor as well as inner retinal responses of the ERG. *Doc Ophthalmol* 1999;98:153–73.
- 44 Bradshaw K, Allen L, Trump D, Hardcastle A, George N, Moore A. A comparison of ERG abnormalities in *XLRS* and *XLCSNB*. *Doc Ophthalmol* 2004;108:135–45.
- 45 Sieving PA, Bingham EL, Kemp J, Richards J, Hiriyanna K. Juvenile X-linked retinoschisis from *XLRS1* Arg213Trp mutation with preservation of the electroretinogram scotopic b-wave. *Am J Ophthalmol* 1999;128:179–84.
- 46 Nakamura M, Ito S, Terasaki H, Miyake Y. Japanese X-linked juvenile retinoschisis: conflict of phenotype and genotype with novel mutations in the *XLRS1* gene. *Arch Ophthalmol* 2001;119:1553–4.
- 47 Azzolini C, Pierro L, Codenotti M, Brancato R. OCT images and surgery of juvenile Macular retinoschisis. *Eur J Ophthalmol* 1997;7:196–200.
- 48 Stanga PE, Chong NH, Reck AC, Hardcastle AJ, Holder GE. Optical coherence tomography and electrophysiology in X-linked juvenile retinoschisis associated with a novel mutation in the *XLRS1* gene. *Retina* 2001;21:78–80.
- 49 Muscat S, Fahad B, Parks S, Keating D. Optical coherence tomography and multifocal electroretinography of X-linked juvenile retinoschisis. *Eye* 2001;15:796–9.
- 50 Eriksson U, Larsson E, Holmstrom G. Optical coherence tomography in the diagnosis of juvenile X-linked retinoschisis. *Acta Ophthalmol Scand* 2004;82:218–23.
- 51 Chan WM, Choy KW, Wang J, Lam DS, Yip WW, Fu W, Pang CP. Two cases of X-linked juvenile retinoschisis with different optical coherence tomography findings and *RS1* gene mutations. *Clin Experiment Ophthalmol* 2004;32:429–32.
- 52 Minami Y, Ishiko S, Takai Y, Kato Y, Kagokawa H, Takamiya A, Nagaoka T, Kinouchi R, Yoshida A. Retinal changes in juvenile X-linked retinoschisis using three dimensional optical coherence tomography. *Br J Ophthalmol* 2005;89:1663–4.
- 53 Apushkin MA, Fishman GA, Janowicz MJ. Correlation of optical coherence tomography findings with visual acuity and macular lesions in patients with X-linked retinoschisis. *Ophthalmology* 2005;112:495–501.
- 54 Souied EH, Goritsa A, Querques G, Coscas G, Soubrane G. Indocyanine green angiography of juvenile X-linked retinoschisis. *Am J Ophthalmol* 2005;140:558–61.
- 55 Apushkin MA, Fishman GA. Use of dorzolamide for patients with X-linked retinoschisis. *Retina* 2006;26:741–5.
- 56 Regillo CD, Tasman WS, Brown GC. Surgical management of complications associated with X-linked retinoschisis. *Arch Ophthalmol* 1993;111:1080–6.
- 57 Lomeo MD, Diaz-Rohena R, Lambert HM. Use of perfluorocarbon liquid in the repair of retinoschisis retinal detachments. *J Ophthalmic Nurs Technol* 1997;16:18–21.
- 58 Aslan O, Batman C, Cekic O, Ozalp S. The use of perfluorodecalin in retinal detachments with retinoschisis. *Ophthalmic Surg Lasers* 1998;29:818–21.
- 59 Koh AH, Hogg CR, Holder GE. The incidence of negative ERG in clinical practice. *Doc Ophthalmol* 2001;102:19–30.
- 60 Renner AB, Kellner U, Cropp E, Foerster MH. Dysfunction of transmission in the inner retina: incidence and clinical causes of negative electroretinogram. *Graefes Arch Clin Exp Ophthalmol* 2006.
- 61 Deutmann AF, Pinckers AJ, Aan de Kerk AL. Dominantly inherited cystoid macular edema. *Am J Ophthalmol* 1976;82:540–8.
- 62 Lewis RA, Lee GB, Martonyi CL, Barnett JM, Falls HF. Familial foveal retinoschisis. *Arch Ophthalmol* 1977;95:1190–6.
- 63 Kabanarou SA, Holder GE, Bird AC, Webster AR, Stanga PE, Vickers S, Harney BA. Isolated foveal retinoschisis as a cause of visual loss in young females. *Br J Ophthalmol* 2003;87:801–3.
- 64 Takano M, Kishi S. Foveal retinoschisis and retinal detachment in severely myopic eyes with posterior staphyloma. *Am J Ophthalmol* 1999;128:472–6.
- 65 Hirakata A, Hida T, Ogasawara A, Iizuka N. Multilayered retinoschisis associated with optic disc pit. *Jpn J Ophthalmol* 2005;49:414–6.
- 66 Gehrig A, White K, Lorenz B, Andrassi M, Clemens S, Weber BH. Assessment of *RS1* in X-linked juvenile retinoschisis and sporadic senile retinoschisis. *Clin Genet* 1999;55:461–5.
- 67 Sharon D, Sandberg MA, Caruso RC, Berson EL, Dryja TP. Shared mutations in *NR2E3* in enhanced S-cone syndrome, Goldmann-Favre syndrome, and many cases of clumped pigmentary retinal degeneration. *Arch Ophthalmol* 2003;121:1316–23.
- 68 Gass JD. Nicotinic acid maculopathy. *Am J Ophthalmol* 1973;76:500–10.
- 69 Spinn MJ, Warren FA, Guyer DR, Klanck JM, Spaide RF. Optical coherence tomography findings in nicotinic acid maculopathy. *Am J Ophthalmol* 2003;135:913–4.
- 70 Dajani HM, Lauer AK. Optical coherence tomography findings in niacin maculopathy. *Can J Ophthalmol* 2006;41:197–200.
- 71 Condon GP, Brownstein S, Wang NS, Kearns JA, Ewing CC. Congenital hereditary (juvenile X-linked) retinoschisis. Histopathologic and ultrastructural findings in three eyes. *Arch Ophthalmol* 1986;104:576–83.
- 72 Kirsch LS, Brownstein S, de Wolff-Rouendaal D. A histopathological, ultrastructural and immunohistochemical study of congenital hereditary retinoschisis. *Can ophthalmol* 1996;31:301–10.
- 73 Molday LL, Hicks D, Sauer CG, Weber BH, Molday RS. Expression of X-linked retinoschisis protein *RS1* in photoreceptor and bipolar cells. *Invest Ophthalmol Vis Sci* 2001;42:816–25.
- 74 Reid SN, Yamashita C, Farber DB. Retinoschisin, a photoreceptor-secreted protein, and its interaction with bipolar and muller cells. *J Neurosci* 2003;23:6030–40.
- 75 Vogel WF, Abdulhussein R, Ford CE. Sensing extracellular matrix: An update on discoidin domain receptor function. *Cell Signal* 2006;18:1108–16.
- 76 Vogel W. Discoidin domain receptors: structural relations and functional implications. *The FASEB Journal* 1999;13:S77–82.
- 77 Takada Y, Fariss RN, Tanikawa A, Zeng Y, Carper D, Bush R, Sieving PA. A retinal neuronal developmental wave of retinoschisin expression begins in ganglion cells during layer formation. *Invest Ophthalmol Vis Sci* 2004;45:3302–12.
- 78 Steiner-Champlaud MF, Sahel J, Hicks D. Retinoschisin forms a multi-molecular complex with extracellular matrix and cytoplasmic proteins: interactions with beta2 laminin and alphaB-crystallin. *Mol Vis* 2006;12:892–901.

- 79 **Hunter DD**, Shah V, Merlie JP, Sanes JR. A laminin-like adhesive protein concentrated in the synaptic cleft of the neuromuscular junction. *Nature* 1989;**338**:229–34.
- 80 **Noakes PG**, Gautam M, Mudd J, Sanes JR, Merlie JP. Aberrant differentiation of neuromuscular junctions in mice lacking α -laminin/laminin beta 2. *Nature* 1995;**374**:258–62.
- 81 **Libby RT**, Lavalley CR, Balkema GW, Brunken WJ, Hunter DD. Disruption of laminin beta2 chain production causes alterations in morphology and function in the CNS. *J Neurosci* 1999;**19**:9399–411.
- 82 **Horwitz J**. Alpha-crystallin can function as a molecular chaperone. *Proc Natl Acad Sci USA* 1992;**89**:10449–53.
- 83 **Fraternali F**, Cavallo L, Musco G. Effects of pathological mutations on the stability of a conserved amino acid triad in retinoschisin. *FEBS Lett* 2003;**544**:21–6.
- 84 **Iannaccone A**, Mura M, Dyka FM, Ciccarelli ML, Yashar BM, Ayyagari R, Jablonski MM, Molday RS. An unusual X-linked retinoschisis phenotype and biochemical characterization of the W112C RS1 mutation. *Vision Res* 2006;**46**:3845–52.
- 85 **Min SH**, Molday LL, Seeliger MW, Dinculescu A, Timmers AM, Janssen A, Tonagel F, Tanimoto N, Weber BH, Molday RS, Hauswirth WW. Prolonged recovery of retinal structure/function after gene therapy in an Rslh-deficient mouse model of X-linked juvenile retinoschisis. *Mol Ther* 2005;**12**:644–51.

BMJ Clinical Evidence—Call for contributors

BMJ Clinical Evidence is a continuously updated evidence-based journal available worldwide on the internet which publishes commissioned systematic reviews. *BMJ Clinical Evidence* needs to recruit new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine, with the ability to write in a concise and structured way and relevant clinical expertise.

Areas for which we are currently seeking contributors:

- Secondary prevention of ischaemic cardiac events
 - Acute myocardial infarction
 - MRSA (treatment)
 - Bacterial conjunctivitis
- However, we are always looking for contributors, so do not let this list discourage you.

Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) valid studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we will publish.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with *BMJ Clinical Evidence* editors to ensure that the final text meets quality and style standards.
- Updating the text every 12 months using any new, sound evidence that becomes available. The *BMJ Clinical Evidence* in-house team will conduct the searches for contributors; your task is to filter out high quality studies and incorporate them into the existing text.
- To expand the review to include a new question about once every 12 months.

In return, contributors will see their work published in a highly-rewarded peer-reviewed international medical journal. They also receive a small honorarium for their efforts.

If you would like to become a contributor for *BMJ Clinical Evidence* or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to CECommissioning@bmjgroup.com.

Call for peer reviewers

BMJ Clinical Evidence also needs to recruit new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity and accessibility of specific reviews within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Reviews are usually 1500–3000 words in length and we would ask you to review between 2–5 systematic reviews per year. The peer review process takes place throughout the year, and our turnaround time for each review is 10–14 days. In return peer reviewers receive free access to *BMJ Clinical Evidence* for 3 months for each review.

If you are interested in becoming a peer reviewer for *BMJ Clinical Evidence*, please complete the peer review questionnaire at www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp